• Research & Development

  Patient Enrollment in Safety Trial for PAH Treatment Completed

  Posted by Pulmonary Hypertension News Moderator on November 12, 2018 at 1:51 pm

  Liquidia Technologies has completed enrollment for the safety part of a Phase 3 trial on LIQ861, an inhaled powder formulation of treprostinil for PAH. Click here to learn more.

  What do you think about this news?

  replied 7 years, 4 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply